Celularity Inc. Files 8-K Under 'Other Events'

Ticker: CELUW · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1752828

Sentiment: neutral

Topics: 8-K, other-events

Related Tickers: CELU

TL;DR

CELU filed an 8-K for 'Other Events' on Sept 2nd. No major news.

AI Summary

Celularity Inc. filed an 8-K on September 3, 2025, reporting an event on September 2, 2025. The filing is categorized under 'Other Events' and does not specify any significant financial transactions or material changes. The company, formerly GX Acquisition Corp., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing indicates a routine update or event for Celularity Inc. without immediate financial implications, suggesting no major corporate actions are being disclosed at this time.

Risk Assessment

Risk Level: low — The filing is a standard 8-K under 'Other Events' and does not disclose any material financial changes or significant corporate actions.

Key Players & Entities

FAQ

What specific event is reported under 'Other Events' in this 8-K filing?

The filing does not specify the exact nature of the 'Other Events' beyond categorizing it as such.

When was the earliest event reported in this filing?

The earliest event reported was on September 2, 2025.

What is Celularity Inc.'s former company name?

Celularity Inc.'s former company name was GX Acquisition Corp.

In which state is Celularity Inc. incorporated?

Celularity Inc. is incorporated in Delaware.

What is the SIC code for Celularity Inc.?

The Standard Industrial Classification (SIC) code for Celularity Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 10 · Accepted 2025-09-02 17:40:11

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELULARITY INC . Dated: September 2, 2025 By: /s/ Robert J. Hariri Name: Robert J. Hariri, M.D., Ph.D. Title: Chairman and CEO -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing